SG10201404970PA - Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes - Google Patents

Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Info

Publication number
SG10201404970PA
SG10201404970PA SG10201404970PA SG10201404970PA SG10201404970PA SG 10201404970P A SG10201404970P A SG 10201404970PA SG 10201404970P A SG10201404970P A SG 10201404970PA SG 10201404970P A SG10201404970P A SG 10201404970PA SG 10201404970P A SG10201404970P A SG 10201404970PA
Authority
SG
Singapore
Prior art keywords
modification
recombinant adenovirus
circumsporozoite protein
protein epitopes
plasmodium circumsporozoite
Prior art date
Application number
SG10201404970PA
Other languages
English (en)
Inventor
Takayuki Shiratsuchi
Moriya Tsuji
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of SG10201404970PA publication Critical patent/SG10201404970PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201404970PA 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes SG10201404970PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/054212 WO2011022002A1 (en) 2009-08-18 2009-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Publications (1)

Publication Number Publication Date
SG10201404970PA true SG10201404970PA (en) 2014-10-30

Family

ID=43607237

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201404970PA SG10201404970PA (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
SG2012011144A SG178476A1 (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012011144A SG178476A1 (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Country Status (16)

Country Link
US (1) US20170348405A1 (ko)
EP (2) EP2467157A4 (ko)
JP (2) JP5947719B2 (ko)
KR (1) KR20120094469A (ko)
CN (2) CN105770880A (ko)
BR (1) BR112012003808A2 (ko)
CA (1) CA2769415A1 (ko)
HK (1) HK1179508A1 (ko)
IL (1) IL217709A (ko)
MX (1) MX339830B (ko)
NZ (1) NZ598703A (ko)
RU (1) RU2585228C2 (ko)
SG (2) SG10201404970PA (ko)
UA (1) UA108081C2 (ko)
WO (2) WO2011022002A1 (ko)
ZA (1) ZA201201286B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014196648A1 (en) * 2013-06-03 2014-12-11 Vlp Therapeutics, Llc Malaria vaccine
CA2998540C (en) * 2015-09-16 2024-04-02 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
EP3405582B1 (en) * 2016-01-21 2020-08-12 Janssen Vaccines & Prevention B.V. An improved adenovirus based malaria vaccine encoding and displaying a malaria antigen
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CN108192876A (zh) * 2017-12-07 2018-06-22 东莞市第八人民医院 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
JP2021178021A (ja) * 2020-05-14 2021-11-18 株式会社三洋物産 遊技機
US20240240203A1 (en) * 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4404947A1 (en) * 2021-09-23 2024-07-31 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066623A (en) * 1993-11-23 2000-05-23 The United States Of America As Represented By The Secretary Of The Navy Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
PL376792A1 (pl) * 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2004101799A2 (en) * 2003-05-14 2004-11-25 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Broadening adenovirus tropism
JP2005287309A (ja) * 2004-03-31 2005-10-20 Dnavec Research Inc 遺伝子導入を増強するための薬剤および方法
DE602005025512D1 (de) * 2004-10-13 2011-02-03 Crucell Holland Bv Verbesserte adenovirusvektoren und deren verwendung
US8765146B2 (en) * 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines

Also Published As

Publication number Publication date
JP2016146837A (ja) 2016-08-18
SG178476A1 (en) 2012-03-29
BR112012003808A2 (pt) 2016-11-16
US20170348405A1 (en) 2017-12-07
WO2011022002A1 (en) 2011-02-24
EP3412306A2 (en) 2018-12-12
AU2010286187A1 (en) 2012-02-16
KR20120094469A (ko) 2012-08-24
ZA201201286B (en) 2013-05-29
MX339830B (es) 2016-06-13
JP2013502221A (ja) 2013-01-24
IL217709A (en) 2016-05-31
JP5947719B2 (ja) 2016-07-06
IL217709A0 (en) 2012-03-29
RU2585228C2 (ru) 2016-05-27
CN105770880A (zh) 2016-07-20
MX2012002131A (es) 2012-04-11
HK1179508A1 (zh) 2013-10-04
CN103025349A (zh) 2013-04-03
NZ598703A (en) 2014-04-30
EP2467157A4 (en) 2014-01-22
JP6293181B2 (ja) 2018-03-14
WO2011022522A1 (en) 2011-02-24
CA2769415A1 (en) 2011-02-24
CN103025349B (zh) 2016-05-18
RU2012110255A (ru) 2013-09-27
EP2467157A1 (en) 2012-06-27
EP3412306A3 (en) 2019-01-02
UA108081C2 (uk) 2015-03-25

Similar Documents

Publication Publication Date Title
HK1179508A1 (zh) 採用免疫原性的瘧原蟲環子孢子蛋白表位的重組腺病毒的修飾
IL267556A (en) A pharmaceutical preparation containing recombinant hcg
EP2729481A4 (en) MANIPULATED POLYPEPTIDES WITH IMPROVED DURABILITY AND REDUCED IMMUNOGENICITY
IL221781B (en) Recombinant compositions of rinderpest virus and uses thereof
SG10201508700XA (en) Recombinant subunit dengue virus vaccine
EP2276499A4 (en) RECOMBINANT DESAMIDED GLIADINE ANTIGEN
IL216619A0 (en) Recombinant production of peptides
ZA201201714B (en) Protein matrix vaccines of improved immunogenicity
GB201005625D0 (en) Immunogenic proteins and compositions
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB201103423D0 (en) Immunogenic proteins and compositions
SI2462237T1 (sl) Postopki za izboljšanje ekspresije rekombinantnega proteina
IL216543A (en) Methods for enhancing production of human recombinant wild strain of beta-glucosidase
ZA201407420B (en) Process for purifying recombinant plasmodium falciparum circumsporozoite protein
IL214257A0 (en) Peptides for vaccine
EP2482843A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
EP2406276A4 (en) METHOD OF RENATURING RECOMBINANT PROTEINS
EP2433645A4 (en) NEW MALARIA VACCINE
GB0917685D0 (en) Antigenic polypeptide
ZA201201387B (en) Bovine herpesvirus vaccine
EP2785369A4 (en) IMMUNOGENIC PLASMODIUM FALCIPARUM ANTIGEN COMPOSITIONS AND USES THEREOF
EP2524041A4 (en) RECOMBINANT ANTIBODY VECTOR
GB201010056D0 (en) Polypeptide vaccine
GB0915735D0 (en) Recombinant protein separation
GB0914019D0 (en) Fusion polypeptide